Ernexa Therapeutics Inc. financial data

Symbol
ERNA on Nasdaq
Location
1035 Cambridge Street, Suite 18 A, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 70.1 % -1.35%
Debt-to-equity 540 %
Return On Equity -1.95K % -697%
Return On Assets -305 % -159%
Operating Margin -2.69K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.85M shares -84.7%
Common Stock, Shares, Outstanding 7.85M shares +45.1%
Entity Public Float 8.9M USD -8.25%
Common Stock, Value, Issued 39K USD +44.4%
Weighted Average Number of Shares Outstanding, Basic 8.23M shares +2179%
Weighted Average Number of Shares Outstanding, Diluted 8.23M shares +2179%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 582K USD
Cost of Revenue 96K USD
General and Administrative Expense 5.28M USD -66.9%
Operating Income (Loss) -9.92M USD +47.1%
Nonoperating Income (Expense) -8.39M USD +67.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18.3M USD +59.2%
Income Tax Expense (Benefit) 28K USD +86.7%
Net Income (Loss) Attributable to Parent -18.3M USD +59.2%
Earnings Per Share, Basic 86 USD/shares +99.8%
Earnings Per Share, Diluted 86 USD/shares +99.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.32M USD +66.9%
Assets, Current 3.38M USD -28.6%
Property, Plant and Equipment, Net 92K USD -12.4%
Operating Lease, Right-of-Use Asset 541K USD -24.8%
Goodwill 2.04M USD 0%
Other Assets, Noncurrent 116K USD -3.33%
Assets 6.17M USD -20%
Accounts Payable, Current 958K USD -56.3%
Employee-related Liabilities, Current 12K USD -88.9%
Accrued Liabilities, Current 859K USD -26.3%
Contract with Customer, Liability, Current 5.34M USD
Liabilities, Current 2.14M USD -78.5%
Operating Lease, Liability, Noncurrent 346K USD -35.2%
Other Liabilities, Noncurrent 112K USD +33.3%
Liabilities 2.6M USD -95.1%
Retained Earnings (Accumulated Deficit) -244M USD -8.13%
Stockholders' Equity Attributable to Parent 3.57M USD
Liabilities and Equity 6.17M USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.07M USD +44.9%
Net Cash Provided by (Used in) Financing Activities 2.25M USD +62.7%
Net Cash Provided by (Used in) Investing Activities -97K USD
Common Stock, Shares Authorized 150M shares +50%
Common Stock, Shares, Issued 7.85M shares +45.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.05M USD -28.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 26M USD +42.2%
Deferred Tax Assets, Gross 26.3M USD -10%
Operating Lease, Liability 552K USD -24.9%
Payments to Acquire Property, Plant, and Equipment 101K USD
Lessee, Operating Lease, Liability, to be Paid 625K USD -26.9%
Property, Plant and Equipment, Gross 257K USD -57.7%
Operating Lease, Liability, Current 206K USD +2.49%
Lessee, Operating Lease, Liability, to be Paid, Year Two 200K USD -25.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 304K USD +10.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +19.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73K USD -39.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 95K USD -41.7%
Preferred Stock, Shares Issued 156K shares 0%
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 393K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 82K USD -98.7%
Additional Paid in Capital 248M USD +37.3%
Preferred Stock, Shares Outstanding 156K shares 0%
Depreciation, Depletion and Amortization 18K USD -53.8%
Deferred Tax Assets, Net of Valuation Allowance 324K USD -97%
Share-based Payment Arrangement, Expense 1.57M USD +23.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%